Search research articles
Contact Us
Filters
Showing results (181-190 of 252) with videos related to
Page
of 26
Sort By:
Clinical Colorectal Cancer
|
September 18, 2022
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF<sup>V600E</sup> Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)
Keitaro Shimozaki, Kenro Hirata, Taro Sato, et al.
International Journal of Clinical Oncology
|
April 30, 2021
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
Takeshi Kato, Yoshinori Kagawa, Yasutoshi Kuboki, et al.
Med (New York, N.Y.)
|
June 20, 2024
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC
Hideaki Bando, Daisuke Kotani, Hironaga Satake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2016
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study
Takeharu Yamanaka, Eiji Oki, Kentaro Yamazaki, et al.
Japanese Journal of Clinical Oncology
|
January 8, 2025
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113
Koh Fukushi, Hiroshi Imaoka, Masafumi Ikeda, et al.
Cancer Medicine
|
August 29, 2023
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Cancer Science
|
September 15, 2019
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
Tetsuya Hamaguchi, Tadamichi Denda, Toshihiro Kudo, et al.
Gastrointestinal Endoscopy
|
June 30, 2025
Optimal number of needle passes in EUS-guided tissue sampling for genomic profiling: a randomized, noncomparative trial
Hirotoshi Ishiwatari, Kazuma Ishikawa, Junya Sato, et al.
Clinical Colorectal Cancer
|
February 8, 2024
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Clinical Colorectal Cancer
|
September 3, 2018
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials
Takayuki Yoshino, Kentaro Yamazaki, Eiji Shinozaki, et al.
Page
of 26
Search research articles
Search
Showing results (181-190 of 252) with videos related to
Sort By:
Page
of 26
Clinical Colorectal Cancer
|
September 18, 2022
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF<sup>V600E</sup> Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)
Keitaro Shimozaki, Kenro Hirata, Taro Sato, et al.
International Journal of Clinical Oncology
|
April 30, 2021
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
Takeshi Kato, Yoshinori Kagawa, Yasutoshi Kuboki, et al.
Med (New York, N.Y.)
|
June 20, 2024
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC
Hideaki Bando, Daisuke Kotani, Hironaga Satake, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2016
12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study
Takeharu Yamanaka, Eiji Oki, Kentaro Yamazaki, et al.
Japanese Journal of Clinical Oncology
|
January 8, 2025
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113
Koh Fukushi, Hiroshi Imaoka, Masafumi Ikeda, et al.
Cancer Medicine
|
August 29, 2023
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Cancer Science
|
September 15, 2019
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
Tetsuya Hamaguchi, Tadamichi Denda, Toshihiro Kudo, et al.
Gastrointestinal Endoscopy
|
June 30, 2025
Optimal number of needle passes in EUS-guided tissue sampling for genomic profiling: a randomized, noncomparative trial
Hirotoshi Ishiwatari, Kazuma Ishikawa, Junya Sato, et al.
Clinical Colorectal Cancer
|
February 8, 2024
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Clinical Colorectal Cancer
|
September 3, 2018
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials
Takayuki Yoshino, Kentaro Yamazaki, Eiji Shinozaki, et al.
Page
of 26